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Abstract
Purpose: The aim of this study was to evaluate treatment results in our hypopharyngeal cancer patients.
Patients and Methods: A total of three hundred and ninety five hypopharyngeal cancer patients received radical
treatment at our hospital; 96% were male. The majority were habitual smokers (88%), alcohol drinkers (73%) and/or
betel quid chewers (51%). All patients received a CT scan or MRI for tumor staging before treatment. The stage
distribution was stage I: 2 (0.5%); stage II: 22 (5.6%); stage III: 57 (14.4%) and stage IV: 314 (79.5%). Radical surgery
was used first in 81 patients (20.5%), and the remaining patients (79.5%) received organ preservation-intended
treatment (OPIT). In the OPIT group, 46 patients received radiotherapy alone, 156 patients received chemotherapy
followed by radiotherapy (CT/RT) and 112 patients received concomitant chemo-radiotherapy (CCRT).
Results: The five-year overall survival rates for stages I/II, III and IV were 49.5%, 47.4% and 18.6%, respectively. There
was no significant difference in overall and disease-specific survival rates between patients who received radical
surgery first and those who received OPIT. In the OPIT group, CCRT tended to preserve the larynx better (p =
0.088), with three-year larynx preservation rates of 44.8% for CCRT and 27.2% for CT/RT. Thirty-seven patients
developed a second malignancy, with an annual incidence of 4.6%.
Conclusions: There was no survival difference between OPIT and radical surgery in hypopharyngeal cancer
patients at our hospital. CCRT may offer better laryngeal preservation than RT alone or CT/RT. However, prospective
studies are still needed to confirm this finding. Additionally, second primary cancers are another important issue for
hypopharyngeal cancer management.
Introduction
Patients with carcinoma of the hypopharynx frequently
have advanced disease at the time of presentation.
These patients have some of the worst prognoses of all
head and neck cancer patients, and combined-modality
therapy is usually required to achieve a cure. The con-
ventional treatment for advanced, but resectable, cases
has been surgery followed by post-operative adjuvant
therapy, and five-year survival rates vary from 10% to
60% [1-5]. Recently, the integration of chemotherapy
and radiotherapy was investigated for organ preservation
in patients with locally advanced hypopharyngeal can-
cers. The results of these prospective trials were
encouraging; they indicated that the larynx could be
preserved using combined chemotherapy and radiother-
apy without compromising overall survival rates [6-10].
Two phase III trials [11,12] of sequential chemother-
apy and radiotherapy for resectable laryngeal or hypo-
pharyngeal cancer revealed survival rates similar to
those achieved with surgery and post-operative irradia-
tion, but the larynx was preserved for many patients in
the former group. On the other hand, a meta-analysis
[13] of six trials comparing induction chemotherapy and
radiotherapy with alternating or concomitant chemo-
radiotherapy (CCRT) revealed a hazard ratio of 0.91
(0.79-1.06) in favor of the latter. This analysis also
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chemotherapy was added concomitantly to radiotherapy.
Growing evidence suggests that CCRT may improve
loco-regional tumor control in locally advanced head
and neck cancers and, more importantly, improve survi-
val rates compared with the sequential regimen or
radiotherapy alone [14,15].
To the best of our knowledge, no existing data
demonstrate whether CCRT could enhance organ pre-
servation in hypopharyngeal cancer patients. In this arti-
cle, we present treatment results for our hypopharyngeal
cancer patients. Furthermore, we determine whether
concomitant use of chemotherapy offers the best chance
of organ preservation.
Patients and Methods
From January 1994 to May 2004, 430 hypopharyngeal
cancer patients were referred for radiotherapy evalua-
tion. We excluded 35 patients who refused radical ther-
apy, leaving 395 patients for analysis. All patients
received computed tomography scans or magnetic reso-
nance imaging (MRI) for staging prior to radical treat-
ment. Initially, 81 patients (20.5%) first received radical
surgery, and the remaining patients (79.5%) underwent
organ preservation-intended therapy (OPIT). Treatment
d e c i s i o n sw e r eb a s e do nt h ep r e f e r e n c eo ft h es e r v i n g
physician and/or patient. In the group that initially
received radical surgery, patients with risk factors such
as positive pathological margin, more than two lymph
node metastases or extracapsular extension of the lymph
nodes also received concomitant chemotherapy when
post-operative radiotherapy was performed. In the OPIT
group, 47 patients received radiotherapy (RT) alone, 188
patients received induction chemotherapy followed by
radiotherapy (CT/RT) and 79 patients received CCRT.
The chemotherapy (CT) regimen, PTL, was detailed in
our previous report [16]. In brief, it consists of 50 mg/
m
2 cisplatin (P) on Day 1, followed by 800 mg/m
2 oral
tegafur (T) per day and 60 mg oral leucovorin (L) per
day for 14 days. The CT was administered at outpatient
clinics in 14-day cycles. In the CT/RT group, re-evalua-
tion after three cycles of chemotherapy led to the termi-
nation of CT if tumor responses were less than partial
responses. Otherwise, PTL regimens were continued for
up to six cycles before radiotherapy. Patients achieving
at least good partial responses at the primary site after
neoadjuvant chemotherapy received radiotherapy or
chemo-radiotherapy for organ preservation.
Radiotherapy was performed by three-field technique;
it consisted of conventional bilateral opposing fields
with a matching anterior lower neck portal. The daily
fractionation size was 1.8 or 2 Gy, with five fractions
per week. The median dose to the gross tumor volume
was 68.4 Gy (range: 60-76 Gy), and to clinical target
volume was 45 Gy (range 45-46 Gy). The planning tar-
get volume was created by adding 5-7 mm margin from
clinical target volume. For the group receiving radical
surgery first, the post-operative radiotherapy dose was
60-68.4 Gy, depending on the pathology risk factor; for
the OPIT group, the dose range was 68.4-76 Gy. The
spinal cord was shielded by customerized cerrobend
block or multi-leaf collimator after 45-46 Gy and the
posterior neck regions were boosted with a 9-12-MeV
electron beam for an additional 14-24 Gy in 7-12 frac-
tions, according to the status of the regional lymph
nodes.
In the organ preservation group, planned neck dissec-
tion was not routinely performed. Salvage surgery or
neck dissection was undertaken when any residual lesion
was noted in the post-treatment evaluation, which was
usually performed three months after radical treatment
or in the case of tumor progression.
All patients were followed in the clinic every one to
two months for the first two years, and then every three
to four months in the third to fifth years. Computer
tomography scans, bone scans, chest X-rays, SMA and
CBC were scheduled routinely (at least annually) for at
least the first three years post-treatment to detect recur-
rence. The primary endpoint of our study was overall
survival rate, with a second endpoint of disease-specific
survival rate (DSS). The duration of survival was defined
as the time from the first date of radical treatment to
the date of the event, which was death for the overall
survival rate or tumor-related mortality for DSS. For
survival with a preserved larynx (OSP), the event was
defined as death or total laryngopharyngectomy. Loco-
regional or distant control meant that no recurrence
could be verified by pathological examination or pro-
gressive changes in serial image studies when no tissue
proof was available. Statistical Package for the Social
Sciences software (SPSS Inc., Chicago, IL) was used for
statistical analysis. The Kaplan-Meier method was used
to estimate survival rates with the log-rank test for sub-
group analyses. A p-value of < 0.05 was considered sig-
nificant. Multivariate analyses were assessed using the
Cox-regression model.
Results
Patient population
The characteristics of all patients are listed in Table 1.
Ninety-six percent were male, and the median age was
56 years (range: 15-87). The majority of patients were
habitual smokers (86.6%), alcohol drinkers (69.6%) and/
or betel quid chewers (47.1%). All patients were re-
staged according to the AJCC 2002 staging system. The
stage distribution was as follows: stage I: 2 (0.5%), stage
II: 22 (5.6%), stage III: 57(14.4%) and stage IV: 314
(79.5%).
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The median follow-up time was 5.09 years. At the time
of analysis, 269 patients had died: of these, 185 died of
local disease, 35 died of distant metastasis and 49 died
of a second primary tumor or other intercurrent disease.
The five-year overall survival rate for all patients was
24.8%. The five-year overall survival rates for stages I/II,
III and IV were 49.5%, 47.4% and 18.6%, respectively (p
< 0.001). The five-year DSS rates for stages I/II, III and
IV were 67.4%, 53.5% and 25.5%, respectively (p <
0.001). The results of subgroup analyses are illustrated
in Table 2.
There was no significant difference in the overall sur-
vival rate or DSS rate between the group of patients
receiving radical surgery first and the organ-preservation
intended treatment group. The five-year overall survival
rate and DSS rate were 18.8% and 24.2% in the radical
surgery-first group and 27% and 35.9% in the OPIT
group, respectively (Figure 1 &2). There was no signifi-
cant difference in the survival rate based on the type of
combination between chemotherapy and radiotherapy.
The five-year overall survival rate and DSS rate were
20.5% and 29.2% for the CT/RT group and 43.1% and
53% for the CCRT group, respectively (p = 0.200 for
overall survival rate and p = 0.397 for DSS). Besides,
when confine the patients into stage III and IV, there is
no significant difference between OPIT group and radi-
cal surgery group in overall survival rates and disease-
free survival rates (p-value = 0.449 and 0.427
respectively).
The five-year overall survival rate was 45.9% and the
DSS rate was 54.4% in patients without evidence of
recurrence. Recurrent patients who suffered from locor-
egional failures had better prognoses than those with
distant failures (Table 2). T-stage, N-stage and recur-
rence were all independent predictors of overall survival
and DSS after multivariate analysis (Table 3).
For patients who only experienced loco-regional
recurrences, salvage surgery with or without adjuvant
radiotherapy and chemotherapy was given under certain
conditions. The five-year DSS rate was 27.8%, and the
overall survival rate was 19.6%. Chemotherapy was given
to patients with distant metastasis with or without loco-
regional control and good performance status, and to
patients with supportive care but with poor performance
status. However, none of these patients survived longer
than three years. The median survival time for patients
with distant metastasis and without loco-regional con-
trol was 1.4 years; patients with recurrence at both dis-
tant and loco-regional sites survived for an average of
1.19 years.
Organ preservation
In the organ preservation group, 93 patients (29.6%) sur-
vived with a preserved larynx at three years. There were
no significant differences in patient characteristics
between C/T+RT and CCRT except for less betel nut
use in CCRT patients. Patients in early T-stage or N-
stage had higher rates of larynx preservation. Smoking,
alcohol drinking or betel quid chewing were not impor-
tant factors for organ preservation. However, patients
who received concomitant chemotherapy had a higher
chance of survival with a preserved larynx when com-
pared with patients who received induction chemother-
apy (CT/RT; 37% vs. 18% of 4-year OSP, p = 0.041;
Figure 3).
Second primary malignancy
During follow-up, 37 patients experienced a second pri-
mary malignancy. There were sixteen head and neck
Table 1 Patient characteristics
Case Numbers
(percentage)
Radical
surgery
group
Organ
preservation
group
P-value
Age, years 0.035
≦55 188 (47.6%) 47 141
> 55 207 (52.4%) 34 173
Gender 0.176
Male 380 (96.2%) 80 300
Female 15 (3.8%) 1 14
Smoking 0.856
Yes 342 (86.6%) 71 271
No 53 (13.4%) 10 43
Alcohol
drinking
0.869
Yes 275 (69.6%) 57 218
No 120 (30.4%) 24 96
Betel nut
chewing
Yes 186 (47.1%) 41 145 0.533
No 209 (52.9%) 40 169
T stage 0.012
T1 19 (4.8%) 4 15
T2 71 (18%) 11 60
T3 73 (18.5%) 6 63
T4 232 (58.7%) 60 172
N stage 0.300
N0 113 (28.6%) 20 93
N1 73 (18.5%) 12 61
N2 154 (39%) 39 115
N3 55 (13.9%) 10 45
Overall
Stage
0.013
I 2 (0.5%) 0 2
II 22 (5.6%) 2 20
III 57 (14.4%) 4 53
IV 314(79.5%) 75 239
Chang et al. Radiation Oncology 2010, 5:91
http://www.ro-journal.com/content/5/1/91
Page 3 of 8cancers (five tongue, four oropharynx, three mouth
floor, two buccal region, one larynx and one submandib-
ular gland), twelve esophageal cancers, twelve lung can-
cers, six bladder cancers and one colon cancer. The
median time to the development of the second primary
malignancy was 2.64 years, with a 4.6% rate of annual
incidence (Figure 4).
Discussion
Symptoms of hypopharyngeal cancers occur late, so
most of them are diagnosed at an advanced stage.
Almost 80% of our patients presented with stage IV dis-
ease. Among head and neck cancers, hypopharyngeal
cancer has the worst prognosis. The five-year overall
survival rate was 24.8% in our series, which is compar-
able to results from other studies where overall survival
rates varied from 10 to 60% [1-3,6-10,12,17-23].
The conventional treatment for locally advanced but
resectable head and neck cancers has been surgery with
post-operative adjuvant therapy depending on the risk
factors for recurrence after surgery. Radiotherapy,
however, is the treatment of choice for unresectable or
medically inoperable patients. To improve survival rates
and preserve organs, a combination of chemotherapy
and radiotherapy was introduced. Most retrospective
studies of head and neck cancers included various sub-
sites (Table 4). Some series revealed a significant rate of
organ preservation with similar survival rates between
surgery and chemo-radiotherapy in head and neck can-
cer patients [1,4,6-12,15,16,18,19,23-27], especially for
laryngeal cancer. In this study, we separated the entire
patient population into two main treatment groups:
radical surgery or organ preservation. There was no sig-
nificant difference in the overall survival rate and DSS
rate between patients who received radical surgery first
and patients in the organ preservation group. However,
patients who survived longer than three years had a
33.2% larynx preservation rate in the latter group.
Two large phase III randomized trials demonstrated
that induction chemotherapy followed by definite radio-
therapy (CT/RT) yielded survival rates similar to those
in patients receiving surgery and irradiation for laryngeal
Table 2 Prognostic factors for survival rates, univariate analysis
Numbers (n) 5-yr OS rate (%) p-value 5-yr DSS rate (%) p-value
Age, years-old 0.747 0.961
≦55 188 25.5 35.2
> 55 207 24.4 31.4
Smoking 0.029 0.075
Yes 342 22.5 30.3
No 53 41.7 49.8
Alcohol drinking 0.081 0.158
Yes 275 22.6 30.8
No 120 29.9 37.3
Betel nut chewing 0.360 0.159
Yes 186 24.4 32.2
No 209 25.0 31.3
T-stage < 0.001 < 0.001
T1 19 54.3 68.6
T2 71 38.1 45.1
T3 69 30.7 38.2
T4 232 17.2 24.4
N-stage < 0.001 < 0.001
N0 113 32.4 40.6
N1 73 36.4 43.6
N2 154 20.6 30.1
N3 55 0 0
Stage < 0.001 < 0.001
I/II 24 49.5 67.4
III 57 47.4 53.5
IV 314 18.6 25.5
Treatment 0.229 0.069
Radical surgery first 81 18.8 24.2
Organ preservation 314 27.0 35.9
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rationale for using induction chemotherapy is the identi-
fication of patients for radiotherapy according to the
high predictability of subsequent radiotherapy response
based on the response to chemotherapy. Therefore,
induction chemotherapy could be used as a surrogate
for patient selection to identify patients who are eligible
for organ preservation. This procedure could avoid the
inevitable severe complications for patients who receive
high-dose RT followed by salvage surgery.
However, the results of a recent RTOG study of laryn-
geal cancer patients [11] challenged the role of induc-
tion chemotherapy in selecting the “right” patients for
organ preservation. Concomitant chemo-radiotherapy
can achieve better rates of organ preservation than
induction chemotherapy selection followed by radiother-
apy. Furthermore, in this study, eleven patients selected
for radical surgery due to a poor response to induction
chemotherapy did not accept radical surgery, so they
received chemotherapy and radiotherapy. All of these
patients achieved complete remission after radical treat-
ment and, consequently, only one patient required a lar-
yngectomy. Although the number is small and there
may be some bias in the patients’ treatment choices, the
use of induction chemotherapy as a predictor of organ
preservation needs further study, especially in an era
where more patients are choosing CCRT.
Concomitant chemotherapy may contribute to the
radiosensitizing effect of radiotherapy and thus improve
tumor control. A large meta-analysis showed that the
survival rate increased significantly when chemotherapy
was added to the treatment of head and neck cancers
[13]. Although the heterogeneity of these 63 trials
(including 10741 patients) limited the identification of
conclusive results, chemotherapy given concomitantly
with radiotherapy still had substantial benefits, corre-
sponding to an absolute five-year survival benefit of 8%.
Our study also found that patients who received CCRT
had higher rates of survival with larynx preservation
(44.8% at three years). Although there was no significant
difference in overall survival, the use of CCRT allows
the possibility of larynx preservation, which may have
an impact on a patient’s social activity and quality of
life.
In retrospective trials of radiotherapy versus surgery,
there is always the possibility of strong selection bias:
usually the surgeons get the “better” patients because
their patients need to be operable and/or resectable. In
this study, a similar bias may have occurred. However,
the OPIT group did not show a worse tumor control or
survival rate than surgical group, and some large
Figure 1 Overall survival curve. Figure 2 Disease-specific survival curve.
Table 3 Multivariate analysis
T-stage N-stage Recurrence
p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI)
5-yr overall survival rate < 0.001 0.332
(0.169-0.652)
< 0.001 0.321
(0.218-0.470)
0.013 0.503
(0.32-0.790)
5-yr disease-specific survival rate 0.003 0.325
(0.151-0.699)
< 0.001 0.290
(0.189-0.445)
0.004 0.435
(0.264-0.717)
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Prospective studies wouldb ev a l u a b l ei na d d r e s s i n g
these issues.
Most patients in our study relapsed at loco-regional
sites, and their five-year overall survival rate was only
19.6%, which suggests that conventional radiotherapy
techniques using bilateral opposing fields may compro-
mise radiation dose coverage of the target after blocking
of the spinal cord at doses of 46-50 Gy. Some studies of
recent modern radiotherapy techniques such as inten-
sity-modulated radiotherapy (IMRT) with concomitant
chemotherapy yielded promising loco-regional control
rates as well as disease-free and overall survival rates for
hypopharyngeal cancer [2,28,29]. Some studies also
revealed that it is possible to decrease the severity of
late toxicities such as dysphagia and aspiration using
IMRT to spare the larynx and swallowing muscles
[30,31].
Second primary cancers were a major cause of death
in this study, with an annual incidence rate of 4.6%. The
median time to the development of a second primary
malignancy was 2.64 years. This incidence is similar to
that reported in our previous study on oral cavity cancer
[16], but the occurrence sites are slightly different. In
oral cavity cancer, the most common second primary
area of occurrence is the head and neck region, espe-
cially the oral cavity area (70.3%). However, in this
study, about 60% (21/37) of cancers occurred below the
clavicle despite all of the patients having similar habits
Figure 3 Survival with larynx preservation curve in the organ
preservation group.
Figure 4 Cumulative incidence of second malignancy.
Table 4 Organ preservation studies of head-and-neck cancers
Author Year of
collection
Case
number
Cancer subsite Treatment Survival rate Organ
preservation rate
VALCSG [11] 332 Stage III/IV LAx Surgery 68% at 2 yr
Induction C/T + RT 68% at 2 yr 64% at 2 yr
Malone et al. [25] 1993-2000 40 Stage III/IV BOT OP+adj-CCRT 74.7% at 2 yr -
Sewnaik et al. [5] 1985-1994 893 HPx Surgery and RT 32% at 5 yr
Adelstein et al. [24,24] 1989-2002 222 All head and neck CCRT 65.7% at 5 yr 62.2% at 5 yr
Soo et al. [4] 119 All head and neck Surgery 50% at 3 yr
#
CCRT 40% at 3 yr
# 45% at 3 yr
Hanna et al. [7] 1996-2002 127 OPx, LAx, HPx, OC CCRT 57% at 3 yr -
Urba et al. [6] 59 BOT, HPx Induction C/T + CCRT 64% at 3 yr 52% at 3 yr
Current series 1994-2004 395 HPx Surgery 18.8% at 5 yr
CCRT 27% at 5 yr 44.8% at 3 yr
37% at 4 yr
#: disease-free survival; Lax: larynx; BOT: base of tongue; HPx: hypopharynx; OPx: oropharynx; OC: oral cavity
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Squamous cell carcinoma of upper aero-digestive tract
(including oral cavity, pharynx, esophagus and lung) is
the most common cancer that occurs in Taiwanese
man, and the incidence of oral cavity cancer and eso-
phageal cancer is increasing 13.1% and 4.1% respectively
in ten years in Taiwan[32]. On the other hand, most of
our patients have the habits of smoking, betel quid
chewing and alcohol consumption, and the concept of
field cancerization from Slaughter et al. [33] may explain
the relative high incidence of second primary malig-
nancy in our patients.
Conclusion
The majority of our hypopharyngeal cancer patients
presented at stage IV. There was no survival difference
b e t w e e nt h eo r g a np r e s e r v a t i o ni n t e n d e dt h e r a p ya n d
radical surgery groups. Patients who received CCRT
had a better chance of survival with a preserved larynx
compared with patients who received induction che-
motherapy. Secondary cancer was a major cause of
death. The median time to the development of a sec-
ond primary malignancy was 2.64 years, with a 4.6%
annual incidence. We suggest that organ preservation
intended therapy, especially CCRT, should be consid-
ered first for patients with advanced hypopharyngeal
cancer patients who refuse, or are unable to undergo,
radical surgery.
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